MyoVista Measurements in Patients With Atherosclerosis & CAD

Status Completed

Clinical Trial Summary

The MyoVista system is a novel electrocardiogram technology that provides non‐invasive assessment of myocardial abnormalities by analyzing energy changes at the cellular level of the myocardium.

Clinical Trial Description

The MyoVista iECG Electrocardiograph is a diagnostic device used to process electrical signals transmitted through electrocardiograph electrodes and to detect ischemia abnormalities based on electrical waveform, patient data, demographics, algorithmic sensitivity and software based informatics. The MyoVista provides the clinician with a standard ECG conventional waveform, along with an additional report derived from the proprietary informatics exclusive to the MyoVista.

The device holds a lot of promise for early intervention to properly diagnose and treat patients under risk timely and effectively. The MyoVista captures and amplifies signals from the myocardial tissue. These signals are then processed and compared to an algorithm that looks for certain changes occurring in these processed waveforms. The changes that have been identified occur much sooner than those processed by a traditional electrocardiogram (ECG). These recordings focus on early detection of myocardial abnormalities by non-linear analysis of electrical activity and physiological phenomenon. This novel assessment might be capable of detecting subclinical myocardial dysfunction in a variety of heart diseases.

The study would compare MyoVista results to subclinical measures of atherosclerosis (CAC and CT angiography) in 200 subjects at risk for coronary disease. Correlations between the MyoVista reading and the presence of calcified plaque, soft plaque, CTA stenosis, will be determined.

This study has the potential to confirm MyoVista as a reliable and sensitive marker of atherosclerosis. Findings may provide a strong indication for the value of a MyoVista test to confirm CAD in clinical practice, and for the clinical application of MyoVista in management of coronary disease and atherosclerosis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02873052
Study type	Observational
Source	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Contact
Status	Completed
Phase
Start date	September 1, 2015
Completion date	February 22, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05052918` - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes	N/A
Recruiting	`NCT04511234` - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease	N/A
Completed	`NCT05906797` - Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis.	N/A
Completed	`NCT03273972` - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers	N/A
Suspended	`NCT02932176` - Machine Learning for Handheld Vascular Studies
Recruiting	`NCT05158257` - Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity	N/A
Completed	`NCT01212900` - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression	Phase 4
Completed	`NCT03697382` - Effect of Daily Steps on Fat Metabolism	N/A
Recruiting	`NCT06230406` - T-Mem GEne in Atherosclerosis
Completed	`NCT03654313` - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus	Phase 1
Completed	`NCT00382564` - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease	N/A
Recruiting	`NCT02894931` - Effects of Dietary Interventions on Serum and Macrophage Atherogenicity	N/A
Completed	`NCT02998918` - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL	N/A
Not yet recruiting	`NCT02578355` - National Plaque Registry and Database	N/A
Recruiting	`NCT02265250` - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
Completed	`NCT03393377` - Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination	N/A
Completed	`NCT02268513` - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
Completed	`NCT02224339` - New Technologies to Determine Carotid Plaque Vulnerability
Completed	`NCT02377310` - Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography	N/A
Completed	`NCT02116829` - Is There Room for Butter in a Healthy Diet?	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

MyoVista Measurements in Patients With Atherosclerosis and CAD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms